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The anti-plasmodial activity of Ailanthus excelsa stem bark was investigated. The methanolic extract inhibited in vitro growth
of chloroquine-sensitive (D10) and resistant strains (W2) of Plasmodium falciparum (IC50 4.6 and 2.8 μg/ml, respectively). The
effect was retained in the chloroform fraction (3.1 and 2.1 μg/ml, respectively). The anti-plasmodial activity could be ascribed to
the impairment of haemoglobin degradation through the inhibition of plasmepsin II activity (IC50 of 13.43±1.74 μg/ml) and of the
haem detoxification to haemozoin.
© 2007 Elsevier B.V. All rights reserved.
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Ailanthus excelsa is a fast-growing and large tree, up to 25 m tall, commonly known as Indian Tree of Heaven. In
traditional medicine the bark is being used as anti-spasmodic and expectorant [1]. A. excelsa has been shown to possess
anti-bacterial [2], anti-leukemic [3] and anti-fungal activities [4]. As for the other Ailanthus species A. excelsa contains
the bitter principles known as quassinoids. Quassinoids isolated from Ailanthus spp. possess several biological
activities including anti-tumor [5], anti-viral [6,7], anti-tuberculosis [8] properties reported in a Review [9].
Quassinoids were also shown to be the active principles responsible for the anti-malarial activity of Ailanthus
altissima. The chloroform extract obtained from the stem and root bark of this plant inhibited in vitro the growth of
Plasmodium falciparum and was active against P. berghei infections in mice [10]. The anti-plasmodial activity has
been mainly referred to the presence of ailanthone, a quassinoid responsible for the anti-malarial activity recently
observed also for the seedlings of A. altissima [11].☆ Mario Dell’Agli and Germana V. Galli contributed equally to this paper.
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intensification of drug resistance over the last 15–20 years.
Modern pharmaceuticals are unavailable and/or unaffordable for the populations living in those areas affected by
malaria. In such conditions non-industrialized countries rely on traditional medicine and locally grown plants for the
cure of malaria. Research Initiative on Traditional Antimalarial Methods (RITAM) is promoting the use of traditional
remedies based on the concept of evidence-based medicine. While A. altissima and other plants of the Simaroubaceae
have been investigated for their efficacy as anti-malarials [12], A. excelsa, which is used as anti-pyretic [1], was never
explored at this regard. The present work was undertaken to evaluate in vitro the anti-plasmodial activity of extracts
from A. excelsa and to investigate the mechanism of action. At this aim the extracts were assayed on chloroquine-
sensitive and resistant strains of P. falciparum at the intra-erythrocytic stage. The survival of malaria parasites in the
host cells relies on the degradation of haemoglobin in the food vacuole with the involvement of several proteinases,
including plasmepsins (PLM), a family of aspartyl proteinases specific to P.f. The inhibition of PLM leads to the
starvation of the parasite [13], then it represents a feasible mechanism of action for the anti-plasmodial effect. In
addition, once haemoglobin is degraded, the parasite detoxifies the excess of released haem by converting it into the
crystalline pigment haemozoin [14]. A synthetic compound, called β-haematin spectroscopically identical to the native
pigment can be obtained in vitro. Quinoline anti-malarials have been shown to inhibit β-haematin formation [15]. Then
we evaluated the ability of A. excelsa to inhibit PLM II and IV and the formation of β-haematin in vitro.
2. Experimental
2.1. Plant material
A. excelsa Roxb (Simaroubaceae), stem bark collected from Zoo garden, Giza, Egypt, in April 2002,was identified
by Prof. Dr. Kamal El Batanony, Professor of Taxonomy and Botany, Faculty of Science, Cairo University. A voucher
was deposited in National Research Centre Herbarium.
2.2. Extraction
Dried powdered stem bark (1 kg) was Soxhlet-extracted with petroleum ether, Et2O, CHCl3, and MeOH (70%) and
concentrated in vacuo. MeOH extract (67.5 g) was added with 500 ml of distilled water and extracted with CHCl3. The
CHCl3 solution was shaken with 10% HCl. The acid layer was made alkaline with NH4OH to pH 9, then it was
extracted with CHCl3. The CHCl3 layer dried was evaporated giving 1.7 g of crude alkaloid chromatographed over
silica gel column using CHCl3 and increasing polarity with MeOH. Elution with chloroform gave canthin-6-one
identified by comparison with the reported spectral data [16,17].
2.3. Drug susceptibility assay on P. falciparum
The CQ-sensitive (D10) and the CQ-resistant (W2) strains of P. falciparum were sustained in vitro as described by
Trager and Jensen [18]. Parasites were maintained at 5% hematocrit (human type A-positive red blood cells) in RPMI
1640 (Gibco BRL, NaHCO3 24 mM) medium with the addition of 10% heat-inactivated A-positive human plasma,
20 mM Hepes (Euroclone), 2 mM glutamine (Euroclone). Compounds were dissolved in either water (chloroquine) or
DMSO and then diluted with the medium to achieve the required concentrations (final DMSO concentration b1%).
Asynchronous cultures with parasitemia of 1–1.5% and 1% final hematocrit were aliquoted into the plates and
incubated for 72 h at 37 °C. Parasite growth was determined spectrophotometrically (OD650) by measuring the activity
of the parasite lactate dehydrogenase (LDH), according to a modified version of Makler's method in control and drug-
treated cultures [19]. Anti-plasmodial activity is expressed as the 50% inhibitory concentrations (IC50), each IC50 value
is the mean±SD of at least three separate experiments performed in duplicate.
2.4. PLMs inhibition assays
Recombinant pro-PLM II and IV were purified from BL21-(DE3) pLysS E. coli (Invitrogen, Milano) according to
Hill J. et al. [20], with slight modifications [21]. Protein concentration was determined according to the method of
Fig. 1. Anti-plasmodial activity of MeOH and CHCl3 extracts against P. falciparum D10 (A) and W2 (B) strains.
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PLM II and IV were activated by addition of one tenth volume of 100 mM sodium acetate buffer pH 4.7 by incubation
at 37 °C for 90 min. The enzyme activity of PLM II and IV was evaluated spectrophotometrically at 300 nm as
described [20].
The CHCl3 fraction from A. excelsa dissolved in DMSO was tested at 5–50 μg/ml (final solvent concentration 1%
of the sample volume). PS777621 [23] was used as the reference compound. The assays were conducted twice in
triplicate. Inhibition curves and IC50 values were calculated by a non-linear regression for sigmoidal curves using
Graph Pad Prism 4.
2.5. β-Haematin inhibitory assay
β-Haematin formation was assayed by a spectrophotometric microassay BHIA (β-Haematin inhibitory assay)
previously reported [24]. Haemin dissolved in DMSO (0.4 μmol/well) was distributed in 96-well microplates. CHCl3
fraction dissolved in DMSO was added in doses ranging from 0.3 to 5 mg/ml. Chloroquine was used as reference
compound and showed an IC50 of 0.9±0.05 mg/ml (mean±SD).
2.6. Cytotoxicity assay
Cytotoxicity was evaluated in human fibroblasts from skin biopsies. Fibroblasts (8×104/well) were grown in 24
well plates with DMEM (Dulbecco's modified Eagle's medium) containing 10% fetal calf serum, 1% penicillin/
streptomycin, and 1% L-glutamine as previously described [25]. Cell proliferation was followed by the MTT (3-[4,5-Fig. 2. Effect of the CHCl3 fraction on PLM II. IC50 value, expressed as the mean±SD of two experiments in triplicate, was 13.4±1.7 μg/ml.
Table 1
Cytotoxicity vs anti-plasmodial activity of the A. excelsa stem bark methanolic extract and CHCl3 fraction
Material HF D10 W2
LC50±SD (μg/ml) IC50±SD (μg/ml) IC50±SD (μg/ml)
MeOH extract 116±19 4.6±1.4 2.8±0.88
CHCl3 fraction 46±7.5 3.1±0.15 2.1±0.58
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fraction (0–100 μg/ml) and LC50 were calculated.
3. Results
The MeOH extract from the stem bark of A. excelsa inhibited parasite growth in a dose dependent manner, with
ICs50 of 4.6 and 2.8 μg/ml on chloroquine-sensitive and -resistant strains, respectively (Fig. 1). After fractionation, the
anti-plasmodial activity was retained by the CHCl3 fraction (IC50 of 3.1 and 2.1 μg/ml on D10 and W2, respectively).
To investigate the mechanism of action, we evaluated whether the CHCl3 fraction inhibited recombinant PLM II
(Fig. 2), PLM IV, and the formation of β-haematin. CHCl3 fraction reduced PLM II activity in a concentration
dependent manner (IC50 of 13.4±1.7 μg/ml, mean±SD), while was inactive against PLM IV. The CHCl3 fraction
inhibited also β-hematin formation dose dependently. At the highest dose tested (5 mg/ml) the inhibition was 37.7%.
As shown in Table 1, the MeOH extract and the CHCl3 fraction were not devoid of cytotoxicity, but the MeOH
extract was less cytotoxic than the CHCl3 fraction (LC50 of 116 μg/ml vs 45.5 μg/ml).
4. Discussion
In the present study it is reported that A. excelsa stem bark methanol extract is active in vitro against both
chloroquine-sensitive and -resistant strains of P. falciparum, similar to A. altissima stem bark [10]. Our results suggest
that extracts from A. excelsa stem bark exert anti-plasmodial activity through the inhibition of PLM II and by halting
the haem detoxification process. Surprisingly, A. excelsa CHCl3 extract was selective against PLM II, being inactive on
PLM IV.
A. excelsa contains quassinoids [27], and β-carboline alkaloids, including canthin-6-one [28]. Canthin-6-one
exhibited anti-plasmodial activity against W2 P.f. clone with IC50 of 2.2 μg/ml, a value very close to that of the CHCl3
fraction, as reported in the present work (Table 1). In a previous study, quassinoids were shown to exhibit anti-malarial
effect through the inhibition of protein synthesis [9]. It cannot be excluded however that quassinoids and canthin-6-one
and/or other β-carboline alkaloids act also against other targets such as the breakdown of haemoglobin and the haem
detoxification to haemozoin. Either, other constituents of A. excelsa stem bark may act as the active principles.
Although the cytotoxicity studies revealed an anti-proliferative effect on mammalian cells by the MeOH extract, the
LC50 on human fibroblasts was 25 and 42 times higher than the IC50 against P. falciparum D10 and W2 strains,
respectively. Cytotoxicity increased when the crude MeOH extract was fractionated to give the CHCl3 fraction, likely
for the presence of higher concentrations of alkaloids which were found cytotoxic against tumor cell lines [29,30]. In
conclusion A. excelsa, as other species of Ailanthus, possesses anti-plasmodial activity. The effect might be ascribable
to the inhibition of haemoglobin cleavage and/or haem detoxification.
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